MedTrace Logo

Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine

NCT02514018 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-10-17

No results posted yet for this study

Summary

The re-activating nature of Varicella Zoster Virus (VZV) may allow life long boosting when used as a vaccine vector in conjunction with HIV to generate durable immunity systemically and at the mucosa. This study aims to characterize mucosal immunity before and after vaccination with a commercial live-attenuated varicella-zoster virus vaccine with respect to immune activation state, mucosal homing properties and VZV-specific effector immune responses in healthy women at low risk for HIV acquisition.

Conditions

  • Healthy

Interventions

BIOLOGICAL

Live-attenuated varicella-zoster virus vaccine

Commercial vaccine used to prevent shingles

Sponsors & Collaborators

  • Kenyan AIDS Vaccine Initiative - Institute of Clinical Research (KAVI-ICR)

    collaborator UNKNOWN

  • University of Nairobi

    collaborator OTHER

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • University of Toronto

    lead OTHER

Principal Investigators

  • Walter Jaoko, MD · KAVI-Institute of Clinical Research / University of Nairobi

  • Kelly MacDonald, MD · University of Toronto

  • Omu Anzala, MD · KAVI-Institute of Clinical Research / University of Nairobi

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-01-31
Completion
2017-07-31

Countries

  • Kenya

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02514018 on ClinicalTrials.gov